Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Xilio Therapeutics (XLO) Accumulated Depreciation & Amortization (2024 - 2025)

Historic Accumulated Depreciation & Amortization for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $8.5 million.

  • Xilio Therapeutics' Accumulated Depreciation & Amortization rose 1983.0% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 1983.0%. This contributed to the annual value of $7.4 million for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $8.5 million for Q3 2025, which was up 1983.0% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $8.5 million in Q3 2025 and a low of $6.3 million during Q1 2024